BRIEF-Questerre Energy updates on Jordan project
* Questerre Energy says finding a way to commercialize this significant oil shale project in a $50 to $70 per barrel environment is main focus Source text for Eikon: Further company coverage:
Jan 9 Celgene Corp raised its 2017 revenue and profit forecasts, as the company benefits from new patient market share gains for its flagship multiple myeloma drug, Revlimid.
The Summit, New Jersey-based company said on Monday it expected earnings per share of $7.10-$7.25 and revenue of $13.0 billion-$13.4 billion for 2017.
Celgene had previously forecast full-year earnings of $6.75-$7.00 per share and net product sales of $12.7 billion-$13.0 billion.
Revlimid's net sales are expected in the range of $8.0 billion to $8.3 billion for 2017. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sriraj Kalluvila)
HONG KONG, May 1Revenue at the world's biggest casino hub of Macau rose 16.3 percent in April, as new resorts helped draw high rollers and casual gamblers to the country's only legal casino hub.